Biotechnology

ReviR Therapeutics Announces Dr. David Dornan as Independent Board Director

SOUTH SAN FRANCISCO, Calif., April 28, 2022 /PRNewswire/ -- ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced today the appointment of Dr.David Dornan as an independent director. "We are thrilled to welcome David to our board of direc...

2022-04-28 22:00 1440

Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting

TAIPEI, April 28, 2022 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838 ) and Aimmax Therapeutics, Inc. ( United States) announced that results from a Phase 2 clinical study of APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), a novel ...

2022-04-28 20:00 1239

Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis

SUZHOU, China, April 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the successful dosin...

2022-04-28 17:06 1885

The Danish National Genome Center Partners with Lifebit to Deliver Nationwide Personalised Medicine

The Danish National Genome Center has awarded Lifebit a four-year contract to implement Lifebit's Federated Trusted Research Environment software, Lifebit CloudOS, withinDenmark's national supercomputing center. LONDON, April 28, 2022 /PRNewswire/ -- Lifebit, whose leading technology enable...

2022-04-28 14:00 2446

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

MELBOURNE, Australia, April 27, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the United Kingdom Medicines & Healt...

2022-04-27 19:40 1476

HistoIndex and Global Liver Experts Advance Stain-free AI Quantification of Hepatocyte Ballooning as a Reproducible Approach and Potential Endpoint for NASH Clinical Trials

* This is a first-of-its-kind international study initiated in 2019 by HistoIndex to examine artificial intelligence (AI)-based approaches that may provide a more reliable way to assess the range of injury recorded as "hepatocyte ballooning" as a clinical trial endpoint by expert hepatopatholo...

2022-04-27 17:34 1957

Samsung Biologics Reports First Quarter 2022 Financial Results

* Q1'22 revenue of KRW 511.3 billion increased 96% compared to Q1'21. * Q1'22 operating profit of KRW 176.4 billion increased 137% compared to Q1'21. * Stable business operations and utilization rates across Plants 1, 2, and 3. * Proactive investments into long-term growth, capacity, and su...

2022-04-27 14:42 1603

Zymo Research Makes Strategic Investment in Star Array to Develop an Automated Nucleic Acid Extraction/Superfast PCR Platform for the POCT Market

IRVINE, Calif., April 27, 2022 /PRNewswire/ -- Zymo Research and Star Array today announced Zymo Research's strategic investment to acquire an interest in Star Array, a privately owned, biomedical technology company based inSingapore. The investment allows Zymo Research and Star Array to combine ...

2022-04-27 11:00 2343

RVAC Medicines, a CBC-Incubated mRNA Platform Company, Raises US$140 Million to Expand R&D and Manufacturing Capacity

Series B financing led by CBC with participation from Temasek's Pavilion Capital, EDBI and GS Holdings RVAC plans to build R&D center and manufacturing facilities in Singapore and China SINGAPORE, April 26, 2022 /PRNewswire/ -- RVAC Medicines Pte. Ltd. ("RVAC"), an emerging messenger RNA (mRNA)...

2022-04-27 10:00 1640

Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018

* Developed in-house by internal R&D Team at Antengene, ATG-018 is an orally-available, small molecule ATR inhibitor that targets DNA Damage Response (DDR) pathways. * The Phase I study will evaluate the safety, pharmacology and preliminary efficacy of ATG-018 in patients with advanced solid ...

2022-04-27 08:30 1880

Seegene unveils world's first commercialized '3 Ct' PCR assay

* Provides Ct value of three targets in one channel; '3 Ct' PCR assay to launch in H1 * "Dream MDx technology" developed based on Seegene's 20-year expertise; combines 19 different patented technologies, including DPO™, TOCE™, MuDT™ * '3 Ct' to lay foundation for automated syndromic testing ...

2022-04-26 20:32 1706

PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study

DAEJEON, South Korea, April 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the positive results from the GLP toxicology study of PMC-403, the Company's novel TIE2-...

2022-04-26 20:30 1273

PharmAbcine Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology

DAEJEON, South Korea, April 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the appointment ofQuan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS to its Scientific Adviso...

2022-04-26 20:00 1317

SOPHiA GENETICS Hits Milestone of One Million Genomic Profiles Analyzed by the SOPHiA DDM™ Platform

BOSTON and LAUSANNE, Switzerland, April 26, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, has reached the milestone of one million genomic profiles analyzed by its SOPHiA DDM™ Platform, securing its position as one of the largest knowledge sharing platform...

2022-04-26 19:57 1688

Getinge Interim Report January-March 2022: Healthy order book but supply chain challenges

GOTHENBURG, Sweden, April 26, 2022 /PRNewswire/ -- "Net sales declined by 6.4% and the order intake fell organically by 4.4% in the quarter," says Mattias Perjos, President & CEO. "However, excluding the strong sales of ventilators in 2021, we had organic growth in both order intake and net sales...

2022-04-26 14:26 1586

ITRI Named a Double Winner at Edison Awards 2022

HSINCHU, April 25, 2022 /PRNewswire/ -- The Edison Awards , one of the world's most revered innovation awards, announced the 2022 winners onApril 21 in Fort Myers, FL. At this year's program,ITRI won two awards in the sci...

2022-04-25 18:15 1609

WuXi AppTec Reports Record First-Quarter In 2022

Revenue Up 71.2% Year-Over-Year to RMB8,474 Million Net Profit Attributable to Owners of the Company Up 9.5% Year-Over-Year to RMB1,643 Million Diluted Earnings Per Share (EPS) Up 3.9% Year-Over-Year to RMB0.53 Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 85.8% Ye...

2022-04-25 17:52 2506

World Malaria Day: Fosun Pharma's Self-Developed Artemisinin Series Become Symbol of China's Innovative Medicines

Together We Build a Malaria-Free World SHANGHAI, April 25, 2022 /PRNewswire/ -- World Malaria Day on April 25, is an occasion that aims to promote global malaria prevention and control. This year, World Malaria Day is marked under the theme "Harness innovation to reduce the malaria disease burde...

2022-04-25 17:00 1815

Huison Virgin DHA Helps Infant Formula Safety Regulation and Innovation Development

* Application Solutions for Virgin DHA in Infant Formula Milk Powder Under the New National Standard XIAMEN, China, April 25, 2022 /PRNewswire/ -- On April 16-17, "Seminar on Infant Formula Perfection, Registration Guidance and Nutritional Ingredients Analysis under the New National Standard" w...

2022-04-25 16:09 1610

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 200 Chinese Patients

SHANGHAI, April 25, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, disclosed that as ofApril 12, 2022, its cell immunotherapy drugs have been successfully ...

2022-04-25 15:08 2410
1 ... 141142143144145146147 ... 281